Epidemiology of <font color="blue">stroke_2</font> <font color="blue">._2</font> Importance of preventive pharmacological strategies in <font color="blue">elderly_1</font> <font color="blue">patients_1</font> <font color="blue">and_1</font> <font color="blue">associated_2</font> <font color="blue">costs_2</font> <font color="blue">._2</font> 
<br>
<br> <font color="blue">Stroke_1</font> is a major cause of <font color="blue">death_1</font> <font color="blue">and_1</font> <font color="blue">disability_1</font> in developed countries . The incidence of <font color="blue">stroke_1</font> increases exponentially with age , yet , traditionally , many medical practitioners have been reluctant to treat <font color="blue">hypertension_1</font> in older patients . Since 1991 , the results of 3 major trials -- the <font color="blue">British_1</font> <font color="blue">Medical_1</font> <font color="blue">Research_1</font> <font color="blue">Council_1</font> <font color="blue">(_1</font> <font color="blue">MRC_1</font> <font color="blue">)_1</font> <font color="blue">trial_1</font> <font color="blue">of_1</font> <font color="blue">treatment_1</font> <font color="blue">in_1</font> <font color="blue">older_1</font> <font color="blue">adults_1</font> <font color="blue">,_1</font> <font color="blue">the_1</font> <font color="blue">Swedish_1</font> <font color="blue">Trial_1</font> <font color="blue">in_1</font> <font color="blue">Old_1</font> <font color="blue">Patients_1</font> <font color="blue">with_1</font> <font color="blue">Hypertension_2</font> ( <font color="blue">STOP_1</font> <font color="blue">-_1</font> <font color="blue">Hypertension_1</font> <font color="blue">)_1</font> <font color="blue">and_1</font> <font color="blue">the_1</font> <font color="blue">Systolic_1</font> <font color="blue">Hypertension_1</font> <font color="blue">in_1</font> <font color="blue">the_1</font> <font color="blue">Elderly_1</font> <font color="blue">Program_1</font> <font color="blue">(_1</font> <font color="blue">SHEP)--have_1</font> conclusively established the benefits of treating older patients ( > 60 years ) with both <font color="blue">diastolic_1</font> <font color="blue">and_1</font> <font color="blue">isolated_1</font> <font color="blue">systolic_1</font> <font color="blue">hypertension_1</font> <font color="blue">._1</font> International guidelines for the management of <font color="blue">hypertension_1</font> <font color="blue">--_1</font> including the Fifth Report of the Joint National Committee , the 1993 report of the World Health Organization and the International Society of <font color="blue">Hypertension_1</font> and the second report of the British Hypertension Society Working Party -- have all been modified to reflect the emerging evidence concerning the benefits of treating older patients . <font color="blue">Cost_2</font> <font color="blue">-_2</font> <font color="blue">effectiveness_2</font> <font color="blue">data_2</font> are similarly in accord with giving high priority to the treatment of older individuals with <font color="blue">hypertension_1</font> <font color="blue">._1</font>